Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline <i>BRCA</i> Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
Nadine Tung, Dana Zakalik, Mark R. Somerfield, for the Hereditary Breast Cancer Guideline Expert Panel
Abstract
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
Topics & Concepts
GuidelineMedicineBreast cancerOncologyFamily medicineCancerBRCA mutationInternal medicineGynecologyPathologyBRCA gene mutations in cancerPARP inhibition in cancer therapyEconomic and Financial Impacts of Cancer